drugset / Trial / NCT06880354
A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Phase 1
Recruiting
37 enrolled
Institute of Hematology & Blood Diseases Hospital, China
AstraZeneca · collabGracell Biotechnologies (Shanghai) Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label, phase I dose-escalation clinical study to evaluate the safety and preliminary efficacy of CLL1 and CD38 dual-target CAR T cell injection in r/r AML subjects.
Timeline
- Start
- 2025-05-22
- Primary completion
- 2028-03-31
- Completion
- 2028-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells | Cell therapy | — | — |